
  
    
      
        Introduction_NNP
        Osteoclasts_NNP are_VBP large_JJ ,_, multinucleated_JJ bone-resorbing_JJ
        cells_NNS derived_VBN from_IN the_DT monocyte-macrophage_JJ lineage_NN [_NN 1_CD ]_NN ._.
        Their_PRP$ bone-resorbing_JJ capacity_NN is_VBZ unique_JJ ;_: no_DT other_JJ cell_NN
        shares_NNS this_DT capability_NN ._. Osteoclasts_NNP are_VBP critical_JJ for_IN both_DT
        the_DT continuous_JJ remodeling_NN of_IN normal_JJ bone_NN tissue_NN as_RB well_RB as_IN
        the_DT repair_NN of_IN fractured_JJ bones_NNS [_NN 2_CD ]_NN ._. During_IN normal_JJ bone_NN
        remodeling_NN ,_, osteoclast-mediated_JJ bone_NN resorption_NN is_VBZ balanced_VBN
        by_IN osteoblast-mediated_JJ bone_NN formation_NN ,_, resulting_VBG in_IN the_DT
        maintenance_NN of_IN skeletal_NN bone_NN mass_NN ._. As_IN a_DT consequence_NN ,_,
        osteoclast_NN dysregulation_NN leads_VBZ to_TO osteoporosis_NNS (_( decreased_VBD
        bone_NN mass_NN caused_VBN by_IN excess_JJ osteoclast_NN activity_NN )_) or_CC to_TO
        osteopetrosis_NNS (_( increased_VBN bone_NN mass_NN caused_VBN by_IN insufficient_JJ
        osteoclast_NN activity_NN )_) ._. Considering_VBG the_DT tremendous_JJ morbidity_NN
        and_CC cost_NN of_IN metabolic_JJ bone_NN diseases_NNS [_NN 3_CD ]_NN ,_, improving_VBG our_PRP$
        molecular_JJ understanding_NN of_IN osteoclast_NN development_NN and_CC
        function_NN is_VBZ critical_JJ towards_IN the_DT design_NN of_IN therapies_NNS to_TO
        combat_VB these_DT prevalent_JJ diseases_NNS ._.
        The_DT molecular_JJ signals_NNS required_VBN for_IN osteoclastogenesis_NNS
        have_VBP recently_RB been_VBN elucidated_JJ [_NN 1_CD 4_CD 5_CD ]_NN ._.
        Receptor-activator_NNP of_IN NFκB_NNP ligand_NN (_( RANKL_NNP )_) ,_, a_DT tumor_NN necrosis_NNS
        factor_NN superfamily_RB ligand_NN expressed_VBN by_IN stromal_NN cells_NNS ,_,
        osteoblasts_NNS ,_, and_CC activated_VBN T_NN cells_NNS ,_, binds_NNS to_TO its_PRP$ cognate_NN
        receptor-activator_JJ of_IN NFκB_NNP (_( RANK_NNP )_) receptor_NN on_IN
        macrophages_NNS /_NN monocytes_NNS ,_, inducing_VBG a_DT signal_NN that_WDT gradually_RB
        transforms_VBZ the_DT macrophages_NNS into_IN osteoclasts_NNS over_IN a_DT period_NN
        of_IN several_JJ days_NNS [_NN 6_CD 7_CD ]_NN ._. While_IN this_DT interaction_NN occurs_VBZ
        largely_RB in_IN the_DT bone_NN microenvironment_NN ,_, it_PRP has_VBZ been_VBN shown_VBN
        that_IN monocytes_NNS from_IN the_DT spleen_NN ,_, peripheral_JJ blood_NN ,_, and_CC
        synovium_NN are_VBP all_DT capable_JJ of_IN RANKL-dependent_NNP osteoclast_NN
        formation_NN [_NN 8_CD ]_NN ._. Convincing_NNP evidence_NN has_VBZ been_VBN generated_VBN
        indicating_VBG that_IN the_DT RANK-RANKL_NNP interaction_NN is_VBZ absolutely_RB
        required_VBN for_IN osteoclastogenesis_NNS [_NN 7_CD ]_NN ;_: in_IN the_DT absence_NN of_IN
        these_DT molecules_NNS ,_, osteoclastogenesis_NNS cannot_NN occur_VB [_NN 9_CD ]_NN
        ._.
        While_IN the_DT RANK-RANKL_NNP signal_NN is_VBZ absolutely_RB required_VBN for_IN
        osteoclastogenesis_NNS ,_, the_DT efficiency_NN of_IN this_DT process_NN is_VBZ
        influenced_VBN by_IN cytokines_NNS ._. The_DT proinflammatory_NN cytokines_NNS
        tumor_NN necrosis_NNS factor_NN alpha_NN ,_, IL-_NNP 1_CD ,_, and_CC IL-_NNP 6_CD augment_VB
        osteoclastogenesis_NNS [_NN 9_CD 10_CD 11_CD ]_NN ,_, while_IN IL-_NNP 10_CD ,_, IL-_NNP 12_CD ,_, IL-_NNP 18_CD ,_,
        and_CC IFN-γ_NNP antagonize_VB osteoclastogenesis_NNS 
        in_IN vitro_NN [_NN 12_CD 13_CD 14_CD 15_CD ]_NN ._. It_PRP is_VBZ
        probable_JJ that_IN cytokines_NNS play_VBP a_DT vital_JJ role_NN in_IN the_DT delicate_JJ
        balance_NN of_IN bone_NN remodeling_NN ,_, and_CC that_IN therapies_NNS based_VBN upon_IN
        their_PRP$ natural_JJ biological_JJ function_NN can_MD be_VB designed_VBN ._.
        IFN-γ_NNP is_VBZ a_DT cytokine_NN secreted_JJ primarily_RB by_IN activated_VBN T_NN
        cells_NNS and_CC NK_NNP cells_NNS whose_WP$ role_NN in_IN bone_NN biology_NN is_VBZ only_RB
        beginning_VBG to_TO be_VB clarified_VBN ._. It_PRP was_VBD originally_RB characterized_VBN
        as_IN a_DT powerful_JJ macrophage_NN activator_NN that_IN upregulated_JJ nitric_JJ
        oxide_NN (_( NO_DT )_) production_NN and_CC MHC_NNP expression_NN in_IN macrophages_NNS [_NN
        16_CD ]_NN ._. It_PRP has_VBZ since_IN been_VBN shown_VBN to_TO stimulate_VB antiviral_JJ and_CC
        antibacterial_NN activities_NNS ,_, to_TO differentiate_VB Th_NNP 0_CD cells_NNS toward_IN
        Th_NNP 1_CD fates_NNS ,_, and_CC to_TO activate_VBP endothelial_NN cells_NNS for_IN leukocyte_NN
        adhesion_NN (_( reviewed_VBN in_IN [_NN 17_CD 18_CD ]_NN )_) ._.
        With_IN respect_NN to_TO osteoclast_NN formation_NN ,_, IFN-γ_NNP is_VBZ known_VBN to_TO
        potently_RB inhibit_VB RANKL-mediated_NNP osteoclastogenesis_NNS in_IN both_DT
        spleen-derived_JJ macrophage_NN cultures_NNS and_CC bone_NN marrow_NN
        coculture_NN systems_NNS [_NN 19_CD 20_CD 21_CD ]_NN ._. It_PRP has_VBZ also_RB been_VBN
        demonstrated_VBN that_WDT mice_NNS defective_JJ in_IN IFN-γ_NNP signaling_VBG have_VBP a_DT
        more_RBR rapid_JJ onset_NN of_IN arthritis_NN and_CC bone_NN resorption_NN compared_VBN
        with_IN wild-type_JJ mice_NNS ,_, suggesting_VBG a_DT protective_JJ role_NN of_IN IFN-γ_NNP
        in_IN early_JJ arthritis_NN [_NN 21_CD 22_CD ]_NN ._.
        There_EX are_VBP situations_NNS ,_, however_RB ,_, in_IN which_WDT the_DT
        anti-osteoclastogenic_JJ effects_NNS of_IN IFN-γ_NNP are_VBP not_RB so_RB clear_JJ ._.
        While_IN IFN-γ_NNP is_VBZ not_RB highly_RB expressed_VBD in_IN joints_NNS of_IN patients_NNS
        with_IN rheumatoid_NN arthritis_NN ,_, diseases_NNS such_JJ as_IN erosive_JJ
        tuberculoid_NN leprosy_NN [_NN 23_CD 24_CD ]_NN and_CC psoriatic_JJ arthritis_NN [_NN 25_CD
        ]_NN are_VBP associated_VBN with_IN high_JJ Th_NNP 1_CD cytokines_NNS such_JJ as_IN IFN-γ_NNP [_NN 26_CD
        ]_NN ._. In_IN these_DT conditions_NNS ,_, tissue_NN destruction_NN has_VBZ been_VBN shown_VBN
        to_TO correlate_VBP with_IN Th_NNP 1_CD -_: mediated_JJ immune_JJ responses_NNS and_CC the_DT
        production_NN of_IN IFN-γ_NNP ,_, indicating_VBG that_IN osteoclastogenesis_NNS may_MD
        occur_VB in_IN the_DT presence_NN of_IN elevated_VBD IFN-γ_NNP [_NN 27_CD ]_NN ._.
        Furthermore_RB ,_, several_JJ clinical_JJ studies_NNS have_VBP failed_VBN to_TO
        demonstrate_VB efficacy_NN of_IN IFN-γ_NNP administration_NN as_IN an_DT
        anti-osteoclastogenic_JJ agent_NN to_TO prevent_VB bone_NN loss_NN [_NN 28_CD 29_CD 30_CD
        ]_NN ._. There_EX seem_VBP to_TO be_VB situations_NNS in_IN which_WDT IFN-γ_NNP does_VBZ not_RB act_VB
        as_IN an_DT anti-osteoclastogenic_JJ agent_NN ._. In_IN particular_JJ ,_, IFN-γ_NNP has_VBZ
        been_VBN shown_VBN to_TO be_VB efficacious_JJ in_IN the_DT treatment_NN of_IN
        osteoporosis_NNS in_IN humans_NNS [_NN 31_CD ]_NN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP demonstrate_VBP that_IN early_JJ exposure_NN
        to_TO RANKL_NNP renders_NNS osteoclast_NN precursors_NNS resistant_JJ to_TO the_DT
        effects_NNS of_IN IFN-γ_NNP ,_, including_VBG inhibition_NN of_IN
        osteoclastogenesis_NNS ._. These_DT effects_NNS were_VBD irreversible_JJ and_CC not_RB
        caused_VBN by_IN inhibition_NN of_IN proximal_NN signaling_VBG at_IN the_DT level_NN of_IN
        STAT_NNP 1_CD or_CC TRAF_NNP 6_CD ,_, suggesting_VBG that_DT resistance_NN to_TO IFN-γ_NNP is_VBZ
        caused_VBN by_IN a_DT complex_JJ differentiation_NN program_NN specifying_VBG the_DT
        osteoclast_NN fate_NN ._. These_DT data_NNS may_MD help_VB explain_VB the_DT
        contradictory_JJ findings_NNS regarding_VBG the_DT effects_NNS of_IN IFN-γ_NNP as_IN an_DT
        inhibitor_NN of_IN osteoclastogenesis_NNS ,_, and_CC also_RB suggest_VBP a_DT model_NN
        of_IN erosive_JJ disease_NN in_IN the_DT presence_NN of_IN IFN-γ_NNP whereby_WRB
        osteoclast_NN precursors_NNS are_VBP exposed_VBN to_TO RANKL_NNP before_IN they_PRP
        enter_VBP the_DT IFN-γ-rich_NNP environment_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cytokines_NNP and_CC growth_NN factors_NNS
          Murine_NNP IFN-γ_NNP ,_, macrophage_NN colony-stimulating_JJ factor_NN ,_,
          tumor_NN necrosis_NNS factor_NN alpha_NN ,_, IL-_NNP 1_CD ,_, IL-_NNP 10_CD and_CC IL-_NNP 6_CD were_VBD
          obtained_VBN from_IN R_NN &_CC D_NNP Systems_NNPS (_( Minneapolis_NNP ,_, USA_NNP )_) ._.
          GST-mRANKL_NNP was_VBD generated_VBN as_IN described_VBN later_RB ._. Human_NNP RANKL_NNP
          was_VBD a_DT gift_NN from_IN Immunex_NNP (_( Seattle_NNP ,_, USA_NNP )_) and_CC was_VBD used_VBN to_TO
          verify_VB the_DT efficiency_NN of_IN GST-RANKL_NNP protein_NN as_IN verified_VBN by_IN
          splenic_JJ osteoclast_NN induction_NN ._.
        
        
          Cell_NNP culture_NN and_CC animals_NNS
          The_DT RAW_NNP 264_CD ._. 7_CD mouse_NN macrophage_NN cell_NN line_NN was_VBD obtained_VBN
          from_IN ATCC_NNP (_( Manassas_NNP ,_, USA_NNP )_) and_CC grown_VBN in_IN a_DT humidified_JJ 5_CD %_NN CO_NNP
          
          2_LS environment_NN at_IN 37_CD °_NN C_NNP ._. Cultures_NNP were_VBD
          maintained_VBN with_IN DMEM_NNP (_( R_NN &_CC D_NNP Systems_NNPS )_) supplemented_JJ with_IN
          10_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC 1_CD %_NN penicillin_NN /_NN streptomycin_NN ._.
          RAW_NNP cell_NN osteoclasts_NNS were_VBD generated_VBN by_IN plating_VBG exactly_RB
          5000_CD RAW_NNP cells_NNS per_IN well_RB in_IN a_DT 96_CD -_: well_RB dish_NN with_IN 200_CD ng_NN /_NN ml_NN
          GST-RANKL_NNP or_CC additional_JJ cytokines_NNS and_CC culturing_VBG for_IN 4_CD -_: 5_CD
          days_NNS ._. In_IN some_DT cultures_NNS ,_, administration_NN of_IN IFN-γ_NNP was_VBD
          delayed_VBN to_TO allow_VB for_IN an_DT early_JJ effect_NN of_IN RANKL_NNP ._.
          Osteoclasts_NNP were_VBD large_JJ ,_, multinucleated_JJ cells_NNS ,_, and_CC
          expressed_VBD high_JJ levels_NNS of_IN tartrate-resistant_JJ acid_NN
          phosphatase_NN (_( TRAP_NNP )_) ._. For_IN western_JJ blots_NNS ,_, RAW_NNP cells_NNS were_VBD
          grown_VBN in_IN six-well_JJ dishes_NNS at_IN 100_CD ,_, 000_CD cells_NNS /_NN well_RB with_IN the_DT
          same_JJ cytokine_NN treatments_NNS ._.
          CBA_NNP /_NN BL_NNP 6_CD mice_NNS (_( Jackson_NNP Labs_NNPS ,_, Bar_NNP Harbor_NNP ,_, USA_NNP )_) were_VBD
          sacrificed_JJ at_IN 6_CD -_: 8_CD weeks_NNS and_CC spleens_NNS aseptically_RB removed_VBN ._.
          Splenocytes_NNP were_VBD mechanically_RB dissociated_JJ by_IN disruption_NN
          through_IN steel_NN mesh_NN ,_, and_CC red_JJ blood_NN cells_NNS were_VBD lysed_JJ using_VBG
          a_DT hypotonic_JJ ammonium_NN chloride_NN solution_NN (_( 82_CD ._. 9_CD g_SYM ammonium_NN
          chloride_NN ,_, 10_CD g_SYM potassium_NN bicarbonate_NN ,_, 0_CD ._. 37_CD g_SYM EDTA_NNP ,_, 1_CD l_NN
          sterile_JJ water_NN for_IN a_DT 10_CD ×_NN solution_NN )_) ._. The_DT remaining_VBG white_JJ
          cells_NNS were_VBD plated_JJ in_IN 96_CD -_: well_RB plates_NNS at_IN 200_CD ,_, 000_CD cells_NNS /_NN well_RB
          with_IN 50_CD ng_NN /_NN ml_NN murine_NN macrophage_NN colony-stimulating_JJ factor_NN
          (_( R_NN &_CC D_NNP Systems_NNPS )_) to_TO preferentially_RB maintain_VB monocyte_NN
          proliferation_NN ._. Large_JJ ,_, multinucleated_JJ ,_, TRAP_NNP +_NN osteoclasts_NNS
          were_VBD generated_VBN by_IN further_JJ addition_NN of_IN 200_CD ng_NN /_NN ml_NN GST-RANKL_NNP
          and_CC culturing_VBG for_IN 4_CD -_: 6_CD days_NNS ._. IFN-γ_NNP (_( 10_CD ng_NN /_NN ml_NN )_) was_VBD added_VBN on_IN
          various_JJ days_NNS in_IN some_DT cultures_NNS ._.
        
        
          TRAP_NNP staining_VBG and_CC quantitation_NN
          Cultures_NNP were_VBD stained_JJ with_IN the_DT osteoclast-specific_JJ
          marker_NN TRAP_NNP using_VBG a_DT kit_NN from_IN Sigma_NNP (_( St_NNP Louis_NNP ,_, USA_NNP )_) ._. In_IN
          osteoclast_NN precursors_NNS ,_, RANKL_NNP induced_VBD increasing_VBG TRAP_NNP
          expression_NN until_IN virtually_RB 100_CD %_NN of_IN mononuclear_NN cells_NNS were_VBD
          highly_RB TRAP-positive_NNP ._. Fusion_NNP and_CC multinucleation_NN
          subsequently_RB occurred_VBD in_IN proportion_NN to_TO the_DT magnitude_NN of_IN
          the_DT RANKL_NNP stimulus_NN ._.
          Osteoclasts_NNP were_VBD counted_VBN using_VBG three_CD equivalent_NN
          methods_NNS ,_, optimized_JJ for_IN the_DT extent_NN of_IN osteoclastogenesis_NNS ._.
          For_IN extremely_RB robust_JJ osteoclast_NN cultures_NNS ,_, manual_JJ tracing_VBG
          and_CC digital_JJ quantitation_NN of_IN a_DT photographed_VBN osteoclast_NN
          area_NN was_VBD the_DT best_JJS measure_NN due_JJ to_TO extensive_JJ fusion_NN and_CC
          multinucleation_NN between_IN cells_NNS (_( Fig_NNP ._. 1_LS )_) ._. Less_JJR robust_JJ
          cultures_NNS with_IN 80_CD -_: 150_CD osteoclasts_NNS per_IN well_RB were_VBD more_RBR
          accurately_RB quantitated_JJ by_IN counting_VBG individual_JJ osteoclasts_NNS
          (_( Fig_NNP ._. 2_LS )_) ._. For_IN cultures_NNS utilizing_VBG lower_JJR levels_NNS of_IN RANKL_NNP
          and_CC low_JJ osteoclast_NN numbers_NNS ,_, densitometric_JJ quantitation_NN of_IN
          TRAP_NNP was_VBD a_DT more_RBR sensitive_JJ measure_NN of_IN osteoclastogenesis_NNS
          (_( Fig_NNP ._. 2_LS d_SYM )_) ._.
        
        
          Purification_NNP of_IN GST-RANKL_NNP
          GST-RANKL_NNP was_VBD purified_JJ as_IN described_VBN previously_RB [_NN 32_CD ]_NN
          ._. Briefly_NNP ,_, a_DT fragment_NN of_IN murine_NN RANKL_NNP cDNA_NN was_VBD cloned_VBN
          inframe_NN into_IN the_DT pGEX-_NN 4_CD T_NN vector_NN (_( Amersham_NNP Pharmacia_NNP ,_,
          Piscataway_NNP ,_, USA_NNP )_) and_CC expressed_VBD in_IN BL_NNP 21_CD bacteria_NNS (_( Amersham_NNP
          Pharmacia_NNP )_) induced_VBN with_IN 0_CD ._. 1_CD mM_NN IPTG_NNP (_( Gibco_NNP )_) for_IN 5_CD hours_NNS
          at_IN 30_CD °_NN C_NNP ._. Bacteria_NNP were_VBD lysed_JJ ,_, and_CC soluble_JJ proteins_NNS were_VBD
          recovered_VBN using_VBG glutathione-agarose_JJ beads_NNS (_( Amersham_NNP
          Pharmacia_NNP )_) ._. Protein_NNP purity_NN was_VBD assessed_VBN by_IN SDS-PAGE_NNP with_IN
          Coomassie_NNP Blue_NNP by_IN comparison_NN with_IN 99_CD %_NN pure_JJ BSA_NNP standards_NNS
          (_( Sigma_NNP )_) and_CC shown_VBN to_TO of_IN equivalent_NN purity_NN (_( Fig_NNP ._. 1_LS a_DT )_) ._. The_DT
          bioactivity_NN of_IN GST-RANKL_NNP was_VBD verified_VBN by_IN RAW_NNP cell_NN
          osteoclastogenesis_NNS and_CC TRAP_NNP expression_NN before_IN
          experimental_JJ use_NN ._. A_DT dose_NN of_IN 200_CD ng_NN /_NN ml_NN GST-RANKL_NNP had_VBD
          equivalent_NN bioactivity_NN to_TO 100_CD ng_NN /_NN ml_NN eukaryotically_RB
          expressed_VBD human_JJ RANKL_NNP protein_NN (_( donated_VBN by_IN Immunex_NNP )_) ._.
        
        
          NO_DT measurement_NN
          NO_DT production_NN was_VBD measured_VBN by_IN the_DT Greiss_NNP reaction_NN
          (_( Promega_NNP ,_, Madison_NNP ,_, USA_NNP )_) ,_, which_WDT spectrophotometrically_RB
          detects_NNS nitrite_NN ,_, a_DT stable_JJ breakdown_NN product_NN of_IN NO_DT whose_WP$
          accumulation_NN reflects_VBZ NO_DT production_NN ._. RAW_NNP cells_NNS were_VBD
          plated_JJ in_IN 96_CD -_: well_RB plates_NNS ,_, and_CC were_VBD stimulated_VBN with_IN
          GST-RANKL_NNP (_( 200_CD ng_NN /_NN ml_NN )_) and_CC /_NN or_CC IFN-γ_NNP (_( 10_CD ng_NN /_NN ml_NN )_) ._. Cell_NNP
          supernatants_NNS were_VBD harvested_VBN and_CC reacted_VBN with_IN 1_CD %_NN
          sulfanilamide_NN and_CC 0_CD ._. 1_CD %_NN naphthyl-ethylenediamine_JJ ._. A_DT
          standard_JJ curve_NN was_VBD constructed_VBN using_VBG dilutions_NNS of_IN sodium_NN
          nitrite_NN ,_, and_CC the_DT absorbance_NN was_VBD measured_VBN at_IN 550_CD nm_NN ._.
          Similar_JJ data_NNS were_VBD obtained_VBN from_IN protein-normalized_JJ data_NNS
          to_TO control_VB for_IN variation_NN in_IN cell_NN number_NN or_CC
          proliferation_NN ._.
        
        
          Western_NNP blotting_VBG
          Cells_NNP were_VBD lysed_JJ with_IN hypotonic_JJ lysis_NNS buffer_NN with_IN
          protease_NN inhibitors_NNS (_( Roche_NNP /_NN Boehringer_NNP Mannheim_NNP ,_,
          Indianapolis_NNP ,_, USA_NNP )_) ._. Thirty_NNP micrograms_NNS of_IN cytoplasmic_JJ
          lysates_NNS or_CC 20_CD μg_NN nuclear_JJ lysates_NNS were_VBD loaded_VBN onto_IN 12_CD %_NN
          SDS-PAGE_NNP gels_NNS and_CC immunoblotted_JJ using_VBG chemiluminescent_NN
          antibodies_NNS ._. Short_JJ exposures_NNS of_IN blots_NNS were_VBD also_RB performed_VBN
          to_TO verify_VB that_IN signals_NNS shown_VBN did_VBD not_RB result_VB from_IN blot_NN
          overexposure_NN ._. All_DT antibodies_NNS were_VBD from_IN Santa_NNP Cruz_NNP (_( Santa_NNP
          Cruz_NNP ,_, USA_NNP )_) except_IN anti-actin_JJ ,_, which_WDT was_VBD purchased_VBN from_IN
          Sigma_NNP ._.
        
        
          Flow_NNP cytometry_NN
          After_IN red_JJ blood_NN cell_NN lysis_NNS ,_, a_DT single_JJ cell_NN suspension_NN
          was_VBD incubated_JJ with_IN antimurine_NN CD_NNP 16_CD /_NN 32_CD (_( Pharmingen_NNP ,_, San_NNP
          Diego_NNP ,_, USA_NNP )_) to_TO block_VB Fc_NNP receptor-mediated_JJ antibody_NN
          binding_JJ ._. Cells_NNP were_VBD then_RB labeled_VBN with_IN
          phycoerythrin-conjugated_JJ anti-_NN CD_NNP 11_CD b_SYM antibodies_NNS
          (_( Pharmingen_NNP )_) or_CC fluorescein-conjugated_JJ RANKL_NNP (_( a_DT gift_NN from_IN
          M_NNP Tondravi_NNP ,_, American_NNP Red_NNP Cross_NNP ,_, Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) as_IN
          described_VBN previously_RB [_NN 33_CD ]_NN ._. Data_NNP were_VBD acquired_VBN using_VBG a_DT
          FACScalibur_NNP instrument_NN (_( Beckton_NNP Dickenson_NNP ,_, Bedford_NNP ,_, MA_NNP ,_,
          USA_NNP )_) and_CC were_VBD analyzed_VBN by_IN Cellquest_NNP software_NN (_( version_NN
          3_CD ._. 1_CD ,_, Beckton_NNP Dickenson_NNP )_) ._. CD_NNP 11_CD b_SYM expression_NN followed_VBD a_DT
          normal-type_JJ distribution_NN in_IN all_DT groups_NNS indicative_JJ of_IN one_CD
          population_NN ,_, and_CC the_DT mean_JJ fluorescent_NN intensity_NN was_VBD thus_RB
          the_DT unit_NN of_IN measure_NN ._. RANK_NNP staining_VBG indicated_VBN two_CD
          populations_NNS ,_, and_CC the_DT relative_JJ size_NN of_IN the_DT high_JJ RANK_NNP
          expressing_VBG (_( RANKhi_NNP )_) population_NN was_VBD thus_RB expressed_VBN on_IN a_DT
          percentage_NN basis_NN ._.
        
      
      
        Results_NNS
        
          IFN-γ_NNP potently_RB and_CC irreversibly_RB inhibits_NNS
          RANKL-induced_NNP osteoclastogenesis_NNS
          To_TO evaluate_VB the_DT effects_NNS of_IN IFN-γ_NNP on_IN
          osteoclastogenesis_NNS ,_, we_PRP utilized_JJ the_DT mouse_NN macrophage_NN cell_NN
          line_NN RAW_NNP 264_CD ._. 7_CD (_( RAW_NNP cells_NNS )_) or_CC splenic_JJ macrophages_NNS from_IN
          CBA_NNP /_NN BL_NNP 6_CD mice_NNS as_IN osteoclast_NN precursors_NNS ._. These_DT cells_NNS have_VBP
          been_VBN demonstrated_VBN to_TO recapitulate_NN critical_JJ aspects_NNS of_IN
          osteoclast_NN formation_NN and_CC activity_NN ,_, including_VBG bone_NN
          resorption_NN ,_, expression_NN of_IN calcitonin_NN receptor_NN ,_,
          multinuclear_NN fusion_NN ,_, and_CC TRAP_NNP expression_NN [_NN 6_CD 34_CD ]_NN ._.
          A_DT dose_NN of_IN 200_CD ng_NN /_NN ml_NN RANKL_NNP generated_VBD numerous_JJ large_JJ ,_,
          multinucleated_JJ osteoclasts_NNS ._. Lower_JJR doses_NNS induced_VBD the_DT
          osteoclast-specific_JJ marker_NN TRAP_NNP in_IN mononuclear_NN cells_NNS but_CC
          generated_VBN substantially_RB fewer_JJR osteoclasts_NNS (_( Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. A_DT
          24_CD -_: hour_NN exposure_NN to_TO IFN-γ_NNP was_VBD sufficient_JJ to_TO potently_RB and_CC
          irreversibly_RB inhibit_VB osteoclastogenesis_NNS in_IN the_DT presence_NN
          of_IN maximal_NN doses_NNS of_IN RANKL_NNP (_( Fig_NNP ._. 2_LS )_) ._. The_DT exposure_NN also_RB
          induced_VBD a_DT stellate_NN cellular_JJ morphology_NN consistent_JJ with_IN
          that_DT of_IN an_DT activated_VBN macrophage_NN (_( Fig_NNP ._. 2_LS )_) ._. The_DT rapid_JJ and_CC
          irreversible_JJ effects_NNS of_IN IFN-γ_NNP on_IN osteoclast_NN inhibition_NN
          indicate_VBP a_DT dominant_JJ effect_NN of_IN this_DT cytokine_NN over_IN RANKL_NNP
          via_IN induction_NN of_IN monocyte_NN differentiation_NN toward_IN the_DT
          activated_VBN macrophage_NN fate_NN ,_, as_IN opposed_VBN to_TO the_DT osteoclast_NN
          fate_NN ,_, when_WRB concomitantly_RB administered_VBN ._.
        
        
          RANKL-pretreated_NNP RAW_NNP cells_NNS are_VBP resistant_JJ to_TO the_DT
          anti-osteoclastogenic_JJ effect_NN of_IN IFN-γ_NNP
          The_DT different_JJ kinetics_NNS between_IN IFN-γ-mediated_NNP
          macrophage_NN activation_NN (_( <_NN 24_CD hours_NNS )_) and_CC RANKL-medicated_NNP
          osteoclastogenesis_NNS (_( 4_CD -_: 5_CD days_NNS )_) prompted_VBD us_PRP to_TO investigate_VB
          the_DT effects_NNS of_IN IFN-γ_NNP on_IN RANKL-pretreated_NNP cells_NNS (_( Fig_NNP ._. 3_LS )_) ._.
          Pretreatment_NNP of_IN RAW_NNP cells_NNS with_IN RANKL_NNP for_IN 48_CD hours_NNS
          rendered_VBD them_PRP resistant_JJ to_TO IFN-γ_NNP ;_: these_DT mononuclear_NN cells_NNS
          formed_VBD multinuclear_NN osteoclasts_NNS despite_IN the_DT presence_NN of_IN
          maximally_RB inhibitory_NN doses_NNS of_IN IFN-γ_NNP (_( 10_CD ng_NN /_NN ml_NN )_) ._.
          To_TO characterize_VB this_DT RANKL-mediated_NNP resistance_NN to_TO
          IFN-γ_NNP ,_, we_PRP performed_VBD a_DT series_NN of_IN dose-response_JJ and_CC time_NN
          course_NN experiments_NNS ._. Pretreatment_NNP with_IN lower_JJR doses_NNS of_IN
          RANKL_NNP was_VBD unable_JJ to_TO overcome_VB IFN-γ_NNP inhibition_NN ,_, indicating_VBG
          that_DT resistance_NN to_TO IFN-γ_NNP required_VBD high_JJ levels_NNS of_IN RANKL_NNP
          pretreatment_NN (_( Fig_NNP ._. 4_LS a_DT ,_, 4_CD b_SYM )_) ._. The_DT duration_NN of_IN RANKL_NNP
          pretreatment_NN was_VBD also_RB important_JJ ;_: the_DT longer_RBR the_DT
          pretreatment_NN phase_NN ,_, the_DT greater_JJR the_DT resistance_NN to_TO IFN-γ_NNP
          (_( Fig_NNP ._. 4_LS c_SYM )_) ._. Together_RB these_DT data_NNS show_VBP that_DT pretreatment_NN
          with_IN RANKL_NNP increases_NNS resistance_NN to_TO IFN-γ-mediated_NNP
          osteoclast_NN inhibition_NN in_IN a_DT dose-dependent_JJ and_CC
          time-dependent_JJ manner_NN ._.
          The_DT mechanism_NN by_IN which_WDT IFN-γ_NNP and_CC RANKL_NNP reciprocally_RB
          inhibit_VBP each_DT other_JJ in_IN pre-osteoclasts_JJ is_VBZ independent_JJ of_IN
          TRAF-_NNP 6_CD and_CC STAT_NNP 1_CD signal_NN transduction_NN ._. Since_IN it_PRP is_VBZ well_RB
          established_VBN that_IN RANK_NNP signaling_VBG is_VBZ mediated_JJ primarily_RB
          through_IN TRAF_NNP 6_CD [_NN 35_CD ]_NN and_CC that_IN IFN-γ_NNP signaling_VBG is_VBZ mediated_JJ
          primarily_RB through_IN STAT_NNP 1_CD [_NN 36_CD 37_CD ]_NN ,_, we_PRP examined_VBD their_PRP$
          expression_NN by_IN western_JJ blot_NN ._. We_PRP failed_VBD to_TO observe_VB
          significant_JJ degradation_NN of_IN TRAF_NNP 6_CD after_IN stimulation_NN with_IN
          IFN-γ_NNP or_CC RANKL_NNP in_IN short-term_JJ or_CC long-term_JJ cultures_NNS (_( Fig_NNP ._.
          5_LS a_DT ,_, 5_CD b_SYM )_) ._.
          Interestingly_RB ,_, IFN-γ-induced_NNP STAT_NNP 1_CD phosphorylation_NN and_CC
          nuclear_JJ translocation_NN was_VBD retained_VBN in_IN pre-osteoclasts_JJ
          (_( Fig_NNP ._. 5_LS c_SYM )_) ._. This_DT result_NN was_VBD confirmed_VBN by_IN electrophoretic_JJ
          mobility_NN shift_NN assays_NNS and_CC the_DT absence_NN of_IN detectable_JJ
          amounts_NNS of_IN the_DT STAT_NNP 1_CD antagonists_NNS SOCS_NNP 1_CD and_CC SOCS_NNP 3_CD (_( data_NNS
          not_RB shown_VBN )_) ._. These_DT results_NNS show_VBP that_IN late_JJ pre-osteoclasts_JJ
          are_VBP capable_JJ of_IN signaling_VBG via_IN JAK-STAT_NNP 1_CD ,_, and_CC suggest_VBP that_IN
          signaling_VBG events_NNS distal_NN to_TO TRAF_NNP 6_CD and_CC STAT_NNP 1_CD modulate_VBP the_DT
          resistance_NN of_IN these_DT cells_NNS to_TO IFN-γ_NNP ._.
        
        
          RANKL_NNP pretreatment_NN inhibits_NNS IFN-γ-induced_NNP
          macrophage_NN activation_NN
          We_PRP next_RB investigated_VBN whether_IN other_JJ IFN-γ_NNP effects_NNS
          besides_IN osteoclast_NN inhibition_NN were_VBD blunted_VBN in_IN
          RANKL-pretreated_NNP cells_NNS ._. IFN-γ-induced_NNP NO_DT production_NN in_IN
          macrophages_NNS was_VBD blunted_VBN in_IN osteoclasts_NNS ,_, probably_RB due_JJ to_TO
          specialization_NN for_IN bone_NN resorption_NN in_IN the_DT latter_JJ
          differentiated_JJ cell_NN (_( Fig_NNP ._. 6_CD )_) ._. Pretreatment_NNP with_IN RANKL_NNP
          inhibited_VBD IFN-γ-induced_NNP NO_DT production_NN in_IN a_DT dose-dependent_JJ
          and_CC time-dependent_JJ manner_NN (_( Fig_NNP ._. 6_CD b_SYM ,_, 6_CD c_SYM )_) ._.
          To_TO expand_VB these_DT findings_NNS ,_, we_PRP investigated_VBD the_DT
          regulation_NN of_IN the_DT cell_NN surface_NN markers_NNS CD_NNP 11_CD b_SYM and_CC RANK_NNP in_IN
          response_NN to_TO induction_NN by_IN RANKL_NNP and_CC IFN-γ_NNP (_( Fig_NNP ._. 7_CD )_) ._. Both_DT
          markers_NNS were_VBD strongly_RB upregulated_JJ by_IN IFN-γ_NNP ._. Consistent_NNP
          with_IN our_PRP$ prior_RB results_VBZ ,_, concomitant_NN treatment_NN of_IN IFN-γ_NNP
          and_CC RANKL_NNP showed_VBD dominance_NN of_IN the_DT IFN-γ_NNP upregulation_NN ,_,
          while_IN pretreatment_NN with_IN RANKL_NNP for_IN 2_CD days_NNS showed_VBD impaired_VBN
          upregulation_NN ._. These_DT data_NNS support_VBP the_DT hypothesis_NNS that_WDT
          sensitivity_NN to_TO IFN-γ_NNP decreases_NNS with_IN increasing_VBG osteoclast_NN
          differentiation_NN and_CC that_IN the_DT mechanism_NN by_IN which_WDT RANKL_NNP and_CC
          IFN-γ_NNP reciprocally_RB inhibit_VBP each_DT other_JJ in_IN pre-osteoclasts_JJ
          is_VBZ mediating_VBG the_DT irreversible_JJ commitment_NN into_IN the_DT
          osteoclast_NN or_CC activated_VBN macrophage_NN lineages_NNS ._.
        
      
      
        Discussion_NNP
        The_DT role_NN of_IN cellular_JJ immunity_NN (_( Th_NNP 1_LS )_) in_IN inflammatory_JJ bone_NN
        loss_NN such_JJ as_IN that_DT seen_VBN in_IN osteomyelitis_NNS and_CC erosive_JJ
        arthritis_NN remains_VBZ unclear_JJ ._. The_DT resolution_NN of_IN this_DT issue_NN is_VBZ
        further_JJ clouded_VBN by_IN the_DT apparent_JJ contradictory_JJ findings_NNS that_IN
        IFN-γ_NNP is_VBZ an_DT extremely_RB potent_JJ anti-osteoclastogenic_JJ factor_NN [_NN
        38_CD ]_NN but_CC it_PRP can_MD be_VB found_VBN at_IN high_JJ levels_NNS in_IN sites_NNS of_IN
        osteolysis_NNS [_NN 39_CD ]_NN ._. To_TO reconcile_VB this_DT controversy_NN we_PRP
        performed_VBD a_DT series_NN of_IN experiments_NNS aimed_VBN at_IN understanding_NN
        how_WRB IFN-γ_NNP could_MD induce_VB either_CC bactericidal_NN effects_NNS via_IN
        macrophage_NN activation_NN or_CC osteoclastic_JJ bone_NN resorption_NN ,_, by_IN
        influencing_VBG the_DT same_JJ progenitor_NN cell_NN in_IN the_DT same_JJ bone_NN
        environment_NN ._.
        We_PRP demonstrate_VBP that_IN pre-osteoclasts_JJ stimulated_VBN with_IN
        RANKL_NNP for_IN 2_CD days_NNS are_VBP rendered_VBN resistant_JJ to_TO the_DT IFN-γ_NNP
        induced_VBD inhibition_NN of_IN osteoclastogenesis_NNS ,_, NO_DT production_NN ,_,
        and_CC upregulation_NN of_IN CD_NNP 11_CD b_SYM and_CC RANK_NNP surface_NN expression_NN ._.
        Surprisingly_RB ,_, this_DT resistance_NN is_VBZ not_RB mediated_JJ by_IN inhibition_NN
        of_IN the_DT JAK-STAT_NNP 1_CD pathway_NN ,_, as_IN STAT_NNP 1_CD phosphorylation_NN ,_, nuclear_JJ
        translocation_NN ,_, and_CC DNA-binding_NNP capabilities_NNS are_VBP all_DT
        preserved_VBN in_IN the_DT late_JJ pre-osteoclast_JJ ._. Together_RB this_DT
        evidence_NN suggests_VBZ that_IN RANKL_NNP modifies_VBZ IFN-γ_NNP effects_NNS
        downstream_JJ of_IN STAT_NNP 1_CD ._.
        The_DT present_JJ results_NNS predict_VBP that_DT timing_NN of_IN IFN-γ_NNP
        exposure_NN will_MD be_VB an_DT important_JJ determinant_NN of_IN its_PRP$ biological_JJ
        function_NN during_IN 
        in_IN vivo_NN osteoclastogenesis_NNS ._. In_IN the_DT
        case_NN of_IN circulating_VBG or_CC peripheral_JJ macrophages_NNS that_WDT have_VBP not_RB
        encountered_VBN osteoclastogenic_JJ quantities_NNS of_IN RANKL_NNP ,_, IFN-γ_NNP
        rapidly_RB induces_VBZ macrophage_NN activation_NN and_CC subsequent_JJ NO_DT
        production_NN ,_, recruiting_VBG these_DT cells_NNS for_IN immune_JJ responses_NNS ._.
        The_DT dominance_NN of_IN IFN-γ_NNP over_IN RANKL_NNP ,_, which_WDT we_PRP observed_VBD 
        in_IN vitro_NN (_( 1_CD ng_NN IFN-γ_NNP counteracts_NNS 200_CD
        ng_NN RANKL_NNP when_WRB simultaneously_RB administered_VBN )_) ,_, probably_RB allows_VBZ
        this_DT macrophage_NN activation_NN to_TO occur_VB even_RB in_IN the_DT presence_NN of_IN
        RANKL_NNP expressed_VBD on_IN circulating_VBG ,_, activated_VBN T_NN cells_NNS [_NN 20_CD 40_CD ]_NN
        ._. In_IN the_DT bone_NN microenvironment_NN ,_, however_RB ,_, more_RBR abundant_JJ
        RANKL_NNP produced_VBN by_IN osteoblasts_NNS /_NN stromal_NN cells_NNS may_MD influence_VB
        certain_JJ monocytes_NNS to_TO commit_VB to_TO the_DT osteoclast_NN lineage_NN [_NN 41_CD
        42_CD ]_NN ._.
        The_DT present_JJ results_NNS predict_VBP that_IN IFN-γ_NNP will_MD not_RB activate_VBP
        these_DT cells_NNS ,_, as_IN they_PRP have_VBP received_VBN an_DT early_JJ RANKL_NNP signal_NN ._.
        The_DT strength_NN of_IN the_DT early_JJ RANKL_NNP signal_NN may_MD be_VB altered_VBN in_IN
        the_DT setting_NN of_IN inflammatory_JJ bone_NN diseases_NNS such_JJ as_IN
        rheumatoid_NN arthritis_NN ,_, in_IN which_WDT high_JJ levels_NNS of_IN RANKL_NNP
        expressed_VBD on_IN either_DT synovial_NN cells_NNS or_CC infiltrating_VBG T_NN cells_NNS
        [_NN 43_CD 44_CD ]_NN may_MD induce_VB osteoclast_NN formation_NN despite_IN the_DT
        presence_NN of_IN exogenous_JJ or_CC endogenous_JJ IFN-γ_NNP ._.
        The_DT potency_NN of_IN IFN-γ_NNP as_IN a_DT macrophage_NN activator_NN and_CC
        osteoclast_NN inhibitor_NN suggests_VBZ a_DT prominent_JJ role_NN for_IN T_NN cells_NNS
        and_CC /_NN or_CC NK_NNP cells_NNS in_IN the_DT regulation_NN of_IN bone_NN resorption_NN ,_, as_IN
        these_DT cells_NNS constitute_VBP the_DT major_JJ source_NN of_IN IFN-γ_NNP [_NN 18_CD ]_NN ._. A_DT
        link_NN between_IN activated_VBN T_NN cells_NNS and_CC osteoclast_NN inhibition_NN by_IN
        IFN-γ_NNP has_VBZ been_VBN highlighted_VBN in_IN a_DT report_NN by_IN Takayanagi_NNP 
        et_CC al_NN ._. ,_, providing_VBG the_DT first_JJ 
        in_IN vivo_NN evidence_NN that_IN the_DT immune_JJ
        system_NN may_MD influence_VB osteoclastogenesis_NNS [_NN 38_CD ]_NN ._.
        Interestingly_RB ,_, other_JJ groups_NNS have_VBP demonstrated_VBN that_WDT
        activated_VBN T_NN cells_NNS induce_VB osteoclastogenesis_NNS via_IN
        upregulation_NN of_IN surface_NN RANKL_NNP ,_, presenting_VBG a_DT dilemma_NN
        regarding_VBG the_DT role_NN of_IN activated_VBN T_NN cells_NNS in_IN
        osteoclastogenesis_NNS [_NN 20_CD 40_CD 45_CD ]_NN ._.
        It_PRP is_VBZ possible_JJ that_IN RANKL_NNP and_CC IFN-γ_NNP expression_NN by_IN
        activated_VBN T_NN cells_NNS may_MD be_VB a_DT major_JJ mechanism_NN by_IN which_WDT T_NN cells_NNS
        control_VBP the_DT fate_NN of_IN osteoclasts_NNS ,_, and_CC that_IN relative_JJ
        expression_NN of_IN both_DT molecules_NNS will_MD dictate_VB whether_IN
        osteoclasts_NNS are_VBP induced_VBN or_CC inhibited_VBD ._. The_DT present_JJ results_NNS
        suggest_VBP that_IN the_DT influence_NN of_IN activated_VBN T_NN cells_NNS on_IN
        osteoclasts_NNS will_MD probably_RB change_VB depending_VBG on_IN when_WRB and_CC
        where_WRB the_DT T_NN cells_NNS encounter_VB the_DT osteoclasts_NNS ._. Bone-resident_NNP
        macrophages_NNS pre-exposed_JJ to_TO RANKL_NNP in_IN the_DT stromal_NN environment_NN
        may_MD be_VB resistant_JJ to_TO the_DT immunoregulatory_NN effects_NNS of_IN IFN-γ_NNP ,_,
        and_CC may_MD thus_RB be_VB better_RBR suited_VBN for_IN bone-remodeling_JJ tasks_NNS ._. In_IN
        contrast_NN ,_, peripheral_JJ blood_NN macrophages_NNS not_RB exposed_VBN to_TO RANKL_NNP
        may_MD be_VB more_RBR responsive_JJ to_TO the_DT macrophage-activating_JJ
        immunoregulatory_NN effects_NNS of_IN IFN-γ_NNP ,_, and_CC may_MD thus_RB be_VB better_RBR
        suited_VBN for_IN antimicrobial_NN activities_NNS ._.
        The_DT molecular_JJ mechanisms_NNS underlying_VBG the_DT contrasting_VBG
        effects_NNS of_IN IFN-γ_NNP and_CC RANKL_NNP remain_VBP elusive_JJ ._. Based_VBN on_IN the_DT
        phenotype_NN of_IN knockout_NN mice_NNS ,_, it_PRP has_VBZ become_VBN clear_JJ that_IN TRAF_NNP 6_CD
        is_VBZ the_DT critical_JJ adapter_NN molecule_NN required_VBN for_IN RANK_NNP
        signaling_VBG during_IN osteoclastogenesis_NNS [_NN 35_CD ]_NN ._. The_DT importance_NN
        of_IN TRAF_NNP 6_CD has_VBZ been_VBN further_JJ explored_JJ in_IN deletion_NN studies_NNS ,_,
        which_WDT correlated_JJ its_PRP$ various_JJ domains_NNS with_IN its_PRP$
        osteoclastogenic_JJ potential_JJ [_NN 46_CD ]_NN ._. A_DT link_NN between_IN IFN-γ_NNP
        and_CC RANK_NNP signaling_VBG via_IN TRAF_NNP 6_CD has_VBZ also_RB been_VBN demonstrated_VBN in_IN
        bone_NN marrow_NN cultures_NNS ,_, in_IN which_WDT IFN-γ_NNP was_VBD shown_VBN to_TO
        accelerate_VB the_DT degradation_NN of_IN TRAF_NNP 6_CD [_NN 38_CD ]_NN ._. In_IN our_PRP$
        studies_NNS ,_, however_RB ,_, we_PRP failed_VBD to_TO observe_VB this_DT TRAF_NNP 6_CD
        degradation_NN ,_, as_IN its_PRP$ expression_NN remained_VBD constant_JJ in_IN both_DT
        short-term_JJ and_CC long-term_JJ cultures_NNS under_IN conditions_NNS where_WRB
        IFN-γ_NNP completely_RB inhibited_VBD osteoclastogenesis_NNS ._. While_IN this_DT
        discrepancy_NN could_MD be_VB explained_VBN by_IN the_DT possibility_NN that_IN RAW_NNP
        cells_NNS represent_VBP a_DT stage_NN of_IN pre-osteoclast_JJ differentiation_NN
        that_WDT is_VBZ not_RB sensitive_JJ to_TO IFN-γ-mediated_NNP TRAF_NNP 6_CD degradation_NN ,_,
        the_DT present_JJ studies_NNS clearly_RB indicate_VBP that_IN IFN-γ_NNP can_MD inhibit_VB
        osteoclastogenesis_NNS via_IN a_DT completely_RB different_JJ
        mechanism_NN ._.
        The_DT retention_NN of_IN Jak-_NNP STAT_NNP 1_CD signaling_VBG in_IN RANKL-stimulated_NNP
        pre-osteoclasts_JJ is_VBZ intriguing_JJ ,_, given_VBN their_PRP$ demonstrated_VBN
        insensitivity_NN to_TO IFN-γ_NNP ._. Since_IN it_PRP is_VBZ known_VBN that_IN osteoclasts_NNS
        express_VBP IFN-γ_NNP receptors_NNS [_NN 47_CD 48_CD ]_NN ,_, it_PRP begs_VBZ the_DT question_NN as_IN
        to_TO why_WRB this_DT pathway_NN remains_VBZ operant_NN ._. One_CD possibility_NN is_VBZ
        that_IN IFN-γ-induced_NNP STAT_NNP 1_CD activation_NN in_IN osteoclasts_NNS leads_VBZ to_TO
        the_DT expression_NN of_IN a_DT unique_JJ set_NN of_IN genes_NNS that_WDT is_VBZ distinct_JJ
        from_IN that_DT in_IN macrophages_NNS ._. Future_JJ studies_NNS designed_VBN to_TO
        understand_VB IFN-γ_NNP signaling_VBG in_IN mature_VBP osteoclasts_NNS are_VBP needed_VBN
        to_TO resolve_VB this_DT issue_NN ._.
        It_PRP is_VBZ noteworthy_JJ to_TO point_VB out_IN that_IN the_DT
        dominant_JJ /_NN irreversible_JJ inhibitory_NN effects_NNS of_IN IFN-γ_NNP on_IN
        osteoclastogenesis_NNS are_VBP fundamentally_RB different_JJ to_TO the_DT
        transient_JJ /_NN reversible_JJ inhibitory_NN effects_NNS of_IN IL-_NNP 4_CD on_IN this_DT
        process_NN ,_, which_WDT are_VBP mediated_JJ by_IN STAT_NNP 6_CD inhibition_NN of_IN NFκB_NNP
        activation_NN [_NN 49_CD 50_CD ]_NN ._. In_IN the_DT present_JJ article_NN ,_, we_PRP
        demonstrate_VBP that_IN RANKL-induced_NNP osteoclastogenesis_NNS cannot_NN be_VB
        recovered_VBN following_VBG exposure_NN to_TO IFN-γ_NNP ._. In_IN contrast_NN ,_, Wei_NNP 
        et_CC al_NN ._. have_VBP demonstrated_VBN that_IN
        pre-osteoclasts_JJ do_VBP not_RB lose_VB their_PRP$ potential_JJ to_TO
        differentiate_VB into_IN mature_VBP osteoclasts_NNS following_VBG a_DT similar_JJ
        exposure_NN to_TO IL-_NNP 4_CD [_NN 50_CD ]_NN ._. It_PRP thus_RB appears_VBZ that_IN IFN-γ_NNP
        anti-osteoclast_JJ activity_NN is_VBZ mediated_JJ by_IN inducing_VBG terminal_NN
        differentiation_NN away_RB from_IN the_DT osteoclast_NN lineage_NN ,_, while_IN
        IL-_NNP 4_CD directly_RB interferes_VBZ with_IN RANKL_NNP signaling_VBG during_IN
        osteoclastogenesis_NNS ._. Collectively_RB ,_, these_DT findings_NNS are_VBP
        consistent_JJ with_IN the_DT observations_NNS that_IN Th_NNP 1_CD cells_NNS are_VBP
        associated_VBN with_IN erosive_JJ disease_NN [_NN 39_CD 50_CD 51_CD ]_NN ,_, that_IN IFN-γ_NNP
        does_VBZ not_RB have_VB antiresorptive_JJ activity_NN [_NN 52_CD 53_CD 54_CD ]_NN ,_, and_CC
        that_IN IL-_NNP 4_CD inhibits_NNS bone_NN resorption_NN [_NN 55_CD 56_CD 57_CD ]_NN ._.
        The_DT present_JJ results_NNS underscore_VBP the_DT importance_NN of_IN
        developing_VBG a_DT complete_JJ understanding_NN of_IN osteoclastogenesis_NNS 
        in_IN vivo_NN with_IN regard_NN to_TO location_NN ,_,
        time_NN ,_, and_CC the_DT signal_NN transduction_NN pathways_NNS involved_VBN ._. It_PRP is_VBZ
        probable_JJ that_WDT signals_NNS such_JJ as_IN IFN-γ_NNP will_MD be_VB interpreted_VBN
        differently_RB by_IN precursors_NNS at_IN various_JJ stages_NNS of_IN development_NN ,_,
        with_IN consequent_JJ effects_NNS on_IN disease_NN ._. Future_JJ studies_NNS in_IN this_DT
        area_NN are_VBP needed_VBN to_TO better_RB understand_VB how_WRB T_NN cells_NNS producing_VBG
        both_DT IFN-γ_NNP and_CC RANKL_NNP mediate_VB immunity_NN and_CC bone_NN resorption_NN ,_,
        and_CC to_TO better_JJR elucidate_NN their_PRP$ role_NN in_IN the_DT pathogenesis_NNS of_IN
        diseases_NNS such_JJ as_IN osteomyelitis_NNS and_CC erosive_JJ arthritis_NN ._.
      
      
        Conclusion_NNP
        We_PRP have_VBP demonstrated_VBN ,_, using_VBG 
        in_IN vitro_NN methods_NNS ,_, that_IN osteoclast_NN
        precursors_NNS exposed_VBN to_TO RANKL_NNP for_IN 1_CD -_: 2_CD days_NNS can_MD be_VB rendered_VBN
        resistant_JJ to_TO maximal_NN osteoclast-inhibitory_JJ doses_NNS of_IN IFN-γ_NNP ._.
        These_DT IFN-γ-resistant_NNP pre-osteoclasts_JJ produced_VBD low_JJ levels_NNS
        of_IN NO_DT upon_IN IFN-γ_NNP stimulation_NN and_CC were_VBD resistant_JJ to_TO
        IFN-γ-induced_NNP ,_, Mac-_NNP 1_CD -_: induced_VBN and_CC RANKL-induced_NNP surface_NN
        expression_NN ,_, suggesting_VBG a_DT broad_JJ resistance_NN to_TO the_DT cellular_JJ
        effects_NNS of_IN IFN-γ_NNP ._. The_DT Jak-_NNP Stat_NNP 1_CD pathway_NN was_VBD intact_JJ in_IN these_DT
        cells_NNS ,_, indicating_VBG that_IN downstream_JJ transcriptional_NN events_NNS
        are_VBP involved_VBN in_IN the_DT inhibition_NN ._. These_DT results_NNS imply_VBP a_DT model_NN
        for_IN arthritic_JJ joints_NNS in_IN which_WDT macrophage_NN precursors_NNS
        entering_VBG an_DT inflamed_JJ joint_JJ are_VBP exposed_VBN to_TO RANKL_NNP and_CC are_VBP
        subsequently_RB rendered_VBN resistant_JJ to_TO the_DT
        anti-osteoclastogenic_JJ effects_NNS of_IN IFN-γ_NNP expressed_VBN by_IN
        activated_VBN T_NN cells_NNS in_IN the_DT synovium_NN ._.
      
      
        Abbreviations_NNP
        BSA_NNP =_SYM bovine_JJ serum_NN albumin_NN ;_: DMEM_NNP =_SYM Dulbecco_NNP 's_POS modified_VBN
        Eagle_NNP 's_POS medium_NN ;_: FACS_NNP =_SYM fluorescence-activated_JJ cell_NN sorting_VBG ;_:
        Fc_NNP =_SYM crystallizable_JJ fragment_NN ;_: FITC_NNP =_SYM fluorescein_NN
        isothiocyanate_NN ;_: IFN_NNP =_SYM interferon_NN ;_: IL_NNP =_SYM interleukin_NN ;_: MHC_NNP =_SYM
        major_JJ histocompatibility_NN complex_JJ ;_: NF_NNP =_SYM nuclear_JJ factor_NN ;_: NO_DT =_SYM
        nitric_JJ oxide_NN ;_: RANK_NNP =_SYM receptor-activator_JJ of_IN NFκB_NNP ;_: RANKL_NNP =_SYM
        receptor-activator_JJ of_IN NFκB_NNP ligand_NN ;_: Th_NNP =_SYM T_NN helper_NN cells_NNS ;_:
        TRAP_NNP =_SYM tartrate-resistant_JJ acid_NN phosphatase_NN ._.
      
    
  
